HealthQuill Overall Survival
Johnson & Johnson’s combination therapy for treating a certain form of cancer without chemotherapy, has been shown to extend patients' lives by more than a year, according to a company statement.
Drugs Health Medical Pharma

J&J’s combination extends lives of cancer patients versus rival drug

Johnson & Johnson’s combination therapy for treating a certain form of cancer without chemotherapy, has been shown to extend patients' lives by more.

Read More
Merck & Co., Inc., announced it has met one of the primary goals during a late-stage trial of its breast cancer therapy, Keytruda.
Drugs Pharma

AstraZeneca, Merck announce promising results for breast cancer in trial 3

Bharti Jayshankar December 13, 2024: AstraZeneca and Merck have announced long-term results from the OlympiA Phase 3 trial, showing that Lynparza (olaparib) significantly.

Read More
Merck & Co., announced its trial drug along with a combination of the company’s Keytruda therapy failed to meet the main goal of overall survival in patients previously treated for a type of metastatic colorectal cancer. 
Drugs Health Pharma

Merck’s trial drug combination for colorectal cancer fails main goal

Merck & Co., announced its trial drug along with a combination of the company’s Keytruda therapy failed to meet the main goal of.

Read More